Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
about
Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertilityRevealing a steroid receptor ligand as a unique PPARγ agonistStructure of a 13-fold superhelix (almost) determined from first principles.RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice.Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling.Liver-specific overexpression of pancreatic-derived factor (PANDER) induces fasting hyperglycemia in miceGlucocorticoids produce whole body insulin resistance with changes in cardiac metabolism.Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.Thermogenic and metabolic antiobesity drugs: rationale and opportunities.Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis.PANcreatic-DERived factor: novel hormone PANDERing to glucose regulation.Epigenomic and transcriptional control of insulin resistance.Human aging in the post-GWAS era: further insights reveal potential regulatory variants.Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry.Acute interaction between hydrocortisone and insulin alters the plasma metabolome in humansNon-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy.Combretum lanceolatum flowers ethanol extract inhibits hepatic gluconeogenesis: an in vivo mechanism study.
P2860
Q24594995-9F103C4D-410D-43DA-A80A-A81A9C134125Q27674914-EA02EFD3-595B-4ACA-BFB1-79AA86224537Q30152952-AAC0AF21-1557-457D-BD65-326C9E28CDC9Q33333978-EF85B08C-6FA5-4EFA-992D-4BCC9FAFCE51Q33781082-B6218775-F5D7-4AD1-8D16-C7F8D85D8FF8Q34197837-9D98FDDF-D3D2-48A2-A0D4-255FDF3B3F57Q36640675-F52A5C52-FFD2-4CB2-B9B9-FE930380FAC2Q36674845-DD3CF562-77E4-441F-9D96-BD9FE3F50E9EQ36772888-7F4DBE53-9062-4B85-A6DC-3188A0BBBCE4Q37418266-253C82D2-8FC1-4DAD-96B3-C0055E76F119Q37888120-5204F375-2B9D-49EC-BA87-C5CA58A26542Q38980163-7B75361B-D5F4-495C-A89A-964AC1CE8271Q39015956-83E52ADD-1FC7-4213-B09C-31611FD5481DQ39495334-C31A4EC3-A44D-487C-929C-16192B60AD7FQ41125941-22E6EFB4-7744-4CDB-8405-2C591380D078Q43167314-07C22899-804C-43C0-9E62-1CFF952CAAE8Q46597789-49067DBD-6FBC-4DCD-BE81-AD439E2050D4
P2860
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@en
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@nl
type
label
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@en
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@nl
prefLabel
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@en
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@nl
P2093
P356
P1476
Hepatic glucocorticoid recepto ...... mal models of type 2 diabetes.
@en
P2093
Alan Cherrington
Amanda Mika
Annika Goos-Nilsson
Bach Nga-Nguyen
Benjamin C Lane
Bradley Zinker
Dale S Edgerton
David W A Beno
Denise Wilcox
James T Link
P304
P356
10.1124/JPET.104.081257
P407
P577
2005-03-22T00:00:00Z